Altamira Therapeutics Successfully Completes Public Offering
Altamira Therapeutics Ltd. (NASDAQ: CYTO), dedicated to advancing RNA delivery technology, has successfully finished its public offering, bringing in $12 million in potential total proceeds. This funding will strengthen the company's ongoing work in the RNA therapeutics sector, extending beyond just liver-related applications.
Offering Overview
The company reported a strategic public offering of around 5,555,556 common shares, which come with associated warrants that could potentially boost gross proceeds. Each share was priced at $0.72, allowing the company to collect roughly $4 million initially. Moreover, if the milestone-linked warrants are fully exercised, an additional $8 million may enhance the company’s financial position.
Understanding the Warrants
The Series A-1 and Series A-2 warrants that accompany the common shares are pivotal to Altamira's financial plans. The Series A-1 warrants can be exercised immediately and will expire contingent upon the announcement of positive biodistribution data, specifically from key pharmaceutical enhancements like the AM-401 and AM-411 nanoparticles.
Conversely, the Series A-2 warrants can also be exercised immediately upon issuance, but they have a longer expiration period. Their expiry depends on the company’s progress with development agreements related to commercializing these nanoparticles in vital markets like the European Union or the United States.
Intended Use of Proceeds
The expected proceeds from this offering are aimed at reinforcing corporate functions and enhancing working capital. This boost in funding underscores the company’s commitment to advancing its proprietary delivery technology systems, which have widespread applications across various RNA modalities.
Changes to Existing Warrants
Furthermore, the company has revised certain existing warrants that were originally issued in July 2023. The amendments include lowering the exercise price from $9.00 to $0.72 per common share and extending the expiration to five years after the offering. This adjustment reflects Altamira's flexible approach to refining their financial obligations and boosting overall competitiveness.
About Altamira Therapeutics
Founded in 2003, Altamira Therapeutics (NASDAQ: CYTO) is based in Hamilton, Bermuda, with substantial research and operational activities located in Basel, Switzerland. The company concentrates on developing peptide-based nanoparticle technologies to improve RNA delivery across various tissues.
Altamira's main pipeline centers on two significant siRNA programs targeting KRAS-driven cancers and rheumatoid arthritis, both currently in preclinical development stages. Additionally, the company has developed a versatile delivery platform suitable for different RNA types, which is also available for licensing to pharmaceutical and biotech companies.
Contact Information
If you have any inquiries, you can reach Altamira Therapeutics via email at hear@altamiratherapeutics.com.
Frequently Asked Questions
How much did Altamira Therapeutics raise in total?
Altamira Therapeutics raised a total of up to $12 million through its public offering.
What will the raised funds be utilized for?
The funds will be directed towards working capital and general corporate purposes, facilitating the advancement of their RNA delivery technologies.
What types of warrants are included in the public offering?
The offering features Series A-1 and Series A-2 common warrants, which could increase total proceeds if exercised.
Where is the headquarters of Altamira Therapeutics located?
The company is headquartered in Hamilton, Bermuda, and it has significant operations based in Basel, Switzerland.
What therapeutic areas does Altamira focus on?
Altamira’s primary focus is on RNA-based treatments that target cancer and rheumatoid arthritis.
